Inducible and selective transgene expression in murine vascular endothelium

Physiological Genomics

Volumn 11, Issue , 2003, Pages 99-107

  Teng, Peter I ^a,b   Dichiara, Maria R ^a   Kömüves, László G ^a   Abe, Keith ^a   Quertermous, Thomas ^b   Topper, James N ^a,b  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene expression; Tetracycline regulation system; Tie2; Transgenic mice; Vascular biology

Indexed keywords

BETA GALACTOSIDASE; DOXYCYCLINE; TETRACYCLINE DERIVATIVE; ANGIOPOIETIN RECEPTOR; PROTEIN TYROSINE KINASE; REPRESSOR PROTEIN; TETRACYCLINE RESISTANCE ENCODING TRANSPOSON REPRESSOR PROTEIN; TETRACYCLINE RESISTANCE-ENCODING TRANSPOSON REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CELL TYPE; CONTROLLED STUDY; EMBRYO; ENDOCARDIUM; ENDOTHELIUM CELL; GENE EXPRESSION; GENE LOCATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSGENE; VASCULAR ENDOTHELIUM; ANIMAL; CHEMISTRY; ENHANCER REGION; GENE EXPRESSION REGULATION; GENE TRANSFER; GENE VECTOR; GENETICS; METABOLISM; R FACTOR; TRANSGENIC MOUSE;

ANIMALIA; MURINAE; MUS MUSCULUS;

ANIMALS; BETA-GALACTOSIDASE; ENDOTHELIUM, VASCULAR; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MICE; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS); R FACTORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TIE-2; REPRESSOR PROTEINS; TRANSGENES;

EID: 0141705588     PISSN: 15312267     EISSN: None     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00059.2002     Document Type: Article

References (43)

1. Agah R, Prasad KS, Linnemann R, Firpo MT, Quertermous T, and Dichek DA. Cardiovascular overexpression of transforming growth factor-beta(1) causes abnormal yolk sac vasculogenesis and early embryonic death. Circ Res 86: 1024-1030, 2000.
2. Almendro N, Bellon T, Rius C, Lastres P, Langa C, Corbi A, and Bernabeu C. Cloning of the human platelet endothelial cell adhesion molecule-1 promoter and its tissue-specific expression. Structural and functional characterization. J Immunol 157: 5411-5421, 1996.
3. Carmeliet P and Collen D. Transgenic mouse models in angiogenesis and cardiovascular disease. J Pathol 190: 387-405, 2000.
4. Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F, Balconi G, Spagnuolo R, Oostuyse B, Dewerchin M, Zanetti A, Angellilo A, Mattot V, Nuyens D, Lutgens E, Clotman F, de Ruiter MC, Gittenberger-de Groot A, Poelmann R, Lupu F, Herbert JM, Collen D, and Dejana E. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98: 147-157, 1999.
5. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW II, Cordon-Cardo C, Yancopoulos GD, and DePinho RA. Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468-472, 1999.
6. Cowan PJ, Shinkel TA, Witort EJ, Barlow H, Pearse MJ, and d'Apice AJ. Targeting gene expression to endothelial cells in transgenic mice using the human intercellular adhesion molecule 2 promoter. Transplantation 62: 155-160, 1996.
7. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, and Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice. Development 121: 1845-1854, 1995.
8. Dumont DJ, Gradwohl GJ, Fong GH, Auerbach R, and Breitman ML. The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors. Oncogene 8: 1293-1301, 1993.
9. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, and Breitman ML. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8: 1897-1909, 1994.
10. Fadel BM, Boutet SC, and Quertermous T. Functional analysis of the endothelial cell-specific Tie2/Tek promoter identifies unique protein-binding elements. Biochem J 330: 335-343, 1998.
11. Fadel BM, Boutet SC, and Quertermous T. Octamer-dependent in vivo expression of the endothelial cell-specific TIE2 gene. J Biol Chem 274: 20376-20383, 1999.
12. Fedorov LM, Tyrsin OY, Sakk O, Ganscher A, and Rapp UR. Generation dependent reduction of tTA expression in double transgenic NZL-2/tTA(CMV) mice. Genesis 31: 78-84, 2001.
13. Fishman GI, Kaplan ML, and Buttrick PM. Tetracycline-regulated cardiac gene expression in vivo. J Clin Invest 93: 1864-1868, 1994.
14. Furth PA, St Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard H, and Hennighausen L. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci USA 91: 9302-9306, 1994.
15. Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN, Fairchild-Huntress V, Dixon KL, Dunmore JH, Gimbrone MA Jr, Falb D, and Huszar D. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet 24: 171-174, 2000.
16. Gossen M and Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551, 1992.
17. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, and Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766-1769, 1995.
18. Goumans MJ, Zwijsen A, van Rooijen MA, Huylebroeck D, Roelen BA, and Mummery CL. Transforming growth factor-β signalling in extraembryonic mesoderm is required for yolk sac vasculogenesis in mice. Development 126: 3473-3483, 1999.
19. Guan J, Guillot PV, and Aird WC. Characterization of the mouse von Willebrand factor promoter. Blood 94: 3405-3412, 1999.
20. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, and Bujard H. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA 93: 10933-10938, 1996.
21. Koni PA, Joshi SK, Temann UA, Olson D, Burkly L, and Flavell RA. Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. J Exp Med 193: 741-754, 2001.
22. Larsson J, Goumans MJ, Sjostrand LJ, van Rooijen MA, Ward D, Leveen P, Xu X, ten Dijke P, Mummery CL, and Karlsson S. Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. EMBO J 20: 1663-1673, 2001.
23. Leveen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, and Betsholtz C. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8: 1875-1887, 1994.
24. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, and Wendel DP. Defective angiogenesis in mice lacking endoglin. Science 284: 1534-1537, 1999.
25. Lindahl P, Johansson BR, Leveen P, and Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277: 242-245, 1997.
26. Lottmann H, Vanselow J, Hessabi B, and Walther R. The Tet-On system in transgenic mice: inhibition of the mouse pdx-1 gene activity by antisense RNA expression in pancreatic β-cells. J Mol Med 79: 321-328, 2001.
27. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, and et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8: 345-351, 1994.
28. Nicklin SA, Reynolds PN, Brosnan MJ, White SJ, Curiel DT, Dominiczak AF, and Baker AH. Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension 38: 65-70, 2001.
29. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, and Li E. Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 97: 2626-2631, 2000.
30. Redfern CH, Coward P, Degtyarev MY, Lee EK, Kwa AT, Hennighausen L, Bujard H, Fishman GI, and Conklin BR. Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice. Nat Biotechnol 17: 165-169, 1999.
31. Rocca B, Loeb AL, Strauss JF III, Vezza R, Habib A, Li H, and FitzGerald GA. Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation. Nat Med 6: 219-221, 2000.
32. Sarao R and Dumont DJ. Conditional transgene expression in endothelial cells. Transgenic Res 7: 421-427, 1998.
33. Sato TN, Qin Y, Kozak CA, and Audus KL. Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci USA 90: 9355-9358, 1993.
34. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, and Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376: 70-74, 1995.
35. Schlaeger TM, Bartunkova S, Lawitts JA, Teichmann G, Risau W, Deutsch U, and Sato TN. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci USA 94: 3058-3063, 1997.
36. Schlaeger TM, Qin Y, Fujiwara Y, Magram J, and Sato TN. Vascular endothelial cell lineage-specific promoter in transgenic mice. Development 121: 1089-1098, 1995.
37. Schultze N, Burki Y, Lang Y, Certa U, and Bluethmann H. Efficient control of gene expression by single step integration of the tetracycline system in transgenic mice. Nat Biotechnol 14: 499-503, 1996.
38. Shockett P, Difilippantonio M, Hellman N, and Schatz DG. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc Natl Acad Sci USA 92: 6522-6526, 1995.
39. Shockett PE and Schatz DG. Diverse strategies for tetracycline-regulated inducible gene expression. Proc Natl Acad Sci USA 93: 5173-5176, 1996.
40. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, and et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359: 693-699, 1992.
41. Soulier S, Stinnakre MG, Lepourry L, Mercier JC, and Vilotte JL. Use of doxycycline-controlled gene expression to reversibly alter milk-protein composition in transgenic mice. Eur J Biochem 260: 533-539, 1999.
42. Walton T, Wang JL, Ribas A, Barsky SH, Economou J, and Nguyen M. Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector. Anticancer Res 18: 1357-1360, 1998.
43. Xie W, Chow LT, Paterson AJ, Chin E, and Kudlow JE. Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFα expression in transgenic mice. Oncogene 18: 3593-3607, 1999.